In last trading session, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) saw 0.34 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $6.65 trading at -$0.18 or -2.64% at ring of the bell on the day assigns it a market valuation of $141.86M. That closing price of ENTA’s stock is at a discount of -167.67% from its 52-week high price of $17.80 and is indicating a premium of 29.17% from its 52-week low price of $4.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 542.61K if we extend that period to 3-months.

For Enanta Pharmaceuticals Inc (ENTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.29. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.14 in the current quarter.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) trade information

Upright in the red during last session for losing -2.64%, in the last five days ENTA remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $6.65 price level, adding 10.5% to its value on the day. Enanta Pharmaceuticals Inc’s shares saw a change of 15.65% in year-to-date performance and have moved -7.89% in past 5-day. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) showed a performance of 13.48% in past 30-days. Number of shares sold short was 2.6 million shares which calculate 5.11 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 56 to the stock, which implies a rise of 88.12% to its current value. Analysts have been projecting 54 as a low price target for the stock while placing it at a high target of 87. It follows that stock’s current price would drop -712.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -712.03% for stock’s current value.

Enanta Pharmaceuticals Inc (ENTA) estimates and forecasts

This year revenue growth is estimated to fall -6.32% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.96M for the same. And 6 analysts are in estimates of company making revenue of 15.61M in the next quarter. Company posted 17.05M and 17.97M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 21.82% while estimates for its earnings growth in next 5 years are of 12.54%.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s Major holders

Insiders are in possession of 6.58% of company’s total shares while institution are holding 96.10 percent of that, with stock having share float percentage of 102.87%. Investors also watch the number of corporate investors in a company very closely, which is 96.10% institutions for Enanta Pharmaceuticals Inc that are currently holding shares of the company. FARALLON CAPITAL MANAGEMENT LLC is the top institutional holder at ENTA for having 2.1 million shares of worth $27.17 million. And as of 2024-06-30, it was holding 9.8914 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1331 of outstanding shares, having a total worth of $25.09 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 629.6 shares of worth $4.19 million or 2.95% of the total outstanding shares. The later fund manager was in possession of 550.17 shares on Dec 31, 2024 , making its stake of worth around $3.66 million in the company or a holder of 2.58% of company’s stock.